TVARDI THERAPEUTICS, INC. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
TVARDI THERAPEUTICS, INC. (TVRD) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $313.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2018-05-09
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2017-12-31 was $0.00.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2017-09-30 was $0.00.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2017-06-30 was $0.00.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2017-03-31 was $313.00K.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2017 was $313.00K.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2015 was $2.09M, a 4.91% decline from fiscal 2014.
- TVARDI THERAPEUTICS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2014 was $2.20M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $0.00 derived: sum of 2 quarters · filed 2018-03-15 | $0.00 derived: sum of 3 quarters · filed 2018-03-15 | $313.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 derived: sum of 2 quarters · filed 2017-11-02 | $313.00K 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $313.00K 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | $313.00K 10-Q · filed 2018-05-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $730.00K derived: sum of 2 quarters · filed 2018-03-15 | $2.09M 10-K · filed 2018-03-15 | |
| 2015-09-30 | $730.00K 10-Q · filed 2016-11-04 | $2.09M 10-Q · filed 2016-11-04 | ||
| 2014-12-31 | $2.20M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |